Neurodegenerative disorders, stroke, and chronic pain are associated with ongoing neuroinflammation which can be partially ameliorated by endocannabinoids. Endocannabinoids are ligands for cannabinoid receptor 1 and 2 (CB1 and CB2). CB1 receptor agonists exhibit psychotropic properties while CB2 receptor agonists have anti-neuroinflammatory effects. Consequently, there is a strong interest in the discovery of CB2 selective agonists to mitigate inflammatory pathologies while being devoid of the psychotropic activity exhibited by CB1 receptor agonists. Endocannabinoids are derived from dietary fatty acids. Anandamide (AEA) is derived from the ?-6 fatty acid arachidonic acid (AA), while docosahexaenoic ethanolamide (DHEA) is derived from the ?-3 fatty acid, docosahexaenoic acid (DHA). The ?-3 and ?-6 endocannabinoids AEA and DHEA are further metabolized by eicosanoid synthesizing enzymes such as CYP epoxygenases to form oxidized endocannabinoid products that have new biological activity. Previous studies have shown that CYP epoxygenases convert AEA into AEA-epoxide that is a CB2 selective agonist. Herein we will test our central hypothesis that, DHEA epoxide (EDP- EA) will display anti-neuroinflammatory action in microglial cells by binding to CB2 receptor and other putative receptors. In order to execute the specific aims of this proposal, we will use a combination of several innovative methods including novel targeted lipidomics (LC-MS/MS) approaches to detect lipid epoxide metabolites, receptor binding and activation studies and neuroinflammation studies using microglial cells. The overall outcome of the project will be the discovery of a new set of lipid signaling endogenous molecules, DHEA epoxides that exhibit anti-neuroinflammatory properties.

Public Health Relevance

Endocannabinoids are diet derived endogenous lipid molecules that elicit beneficial properties similar to cannabis. Herein we propose to elucidate the biological activity with respect to cannabinoid receptor activation and anti-neuroinflammatory action of docosahexaenoyl ethanolamide (DHEA) epoxides.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Research Grants (R03)
Project #
1R03DA042365-01A1
Application #
9387542
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Hillery, Paul
Project Start
2017-07-01
Project End
2019-05-31
Budget Start
2017-07-01
Budget End
2018-05-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Arnold, William R; Weigle, Austin T; Das, Aditi (2018) Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2. J Inorg Biochem 184:88-99
Roy, Jahnabi; Watson, Josephine E; Hong, In Sup et al. (2018) Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides. J Med Chem 61:5569-5579
Carnevale, Lauren N; Arango, Andres S; Arnold, William R et al. (2018) Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase. Biochemistry 57:6489-6499
McDougle, Daniel R; Watson, Josephine E; Abdeen, Amr A et al. (2017) Anti-inflammatory ?-3 endocannabinoid epoxides. Proc Natl Acad Sci U S A 114:E6034-E6043
Roy, Jahnabi; Adili, Reheman; Kulmacz, Richard et al. (2016) Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function. J Pharmacol Exp Ther 359:134-41